AbbVie's Drug Upadacitinib Shows Positive Phase 3 Results for Severe Alopecia Areata Treatment
AbbVie Inc. (NYSE:ABBV) is one of the most undervalued quality stocks to buy according to hedge funds.
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 3,252,861 | $603,796,059 | +77% | 0.1% |
| 2. | Millennium Management Israel Englander | 2,446,607 | $454,139,191 | +416% | 0.22% |
| 3. | 2,253,900 | $418,368,918 | -15% | 0.07% | |
| 4. | Renaissance Technologies Jim Simons | 1,961,998 | $364,186,069 | +61% | 0.48% |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,618,841 | $300,489,266 | -11% | 0.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $198.42 | 42,370 | $8,407,055.40 | 177,292 | 2025-08-12 | Filing | |
| $198.59 | 10,061 | $1,998,013.99 | 58,247 | 2025-08-05 | Filing | |
| $198.27 | 3,234 | $641,238.89 | 68,308 | 2025-08-05 | Filing | |
| $210.54 | 33,132 | $6,975,611.28 | 53,234 | 2025-03-31 | Filing | |
| $209.49 | 25,700 | $5,383,893.00 | 86,366 | 2025-03-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 177,298,707 | $32,910,185,993 | 0.53% | |
| 2. | 147,456,064 | $27,370,794,481 | 0.52% | |
| 3. | 80,024,129 | $14,854,078,825 | 0.56% | |
| 4. | 57,214,407 | $10,620,186,750 | 0.69% | |
| 5. | 41,700,001 | $7,740,354,968 | 0.5% |
News See All
12 Most Undervalued Quality Stocks to Buy According to Hedge Funds
On July 31, Nadia Lovell, UBS senior equity strategist, joined 'The Exchange' on CNBC to discuss why she believes this rally has staying power, and to suggest that investors stay up in quality on secular...
AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to AbbVie's Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is also being recorded.
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc.
AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan
AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts.
Top 15 Low Volatility Healthcare Stocks to Buy Now
A majority of Americans have experienced the frustration of getting a healthcare insurance denial, often times finding no solution despite emails with service providers and phone calls with carriers.
20 Best Low Volatility Stocks to Buy According to Analysts
Consumers remain cautious about potential price hikes, but their biggest concerns about tariff-induced inflation have subsided, according to a University of Michigan survey published on July 18.
Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector
AbbVie Inc. (NYSE:ABBV) stands out as a major player in the pharmaceutical industry, with a broad range of approved treatments.
14 Best Pharma Dividend Stocks to Buy in 2025
The US pharmaceutical industry has undergone notable shifts in recent years, influenced by factors such as the COVID-19 pandemic, expanded collaborations across the value chain, and ongoing changes in...
Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating
AbbVie Inc. (NYSE:ABBV) is one of the high-margin pharma stocks to buy now. AbbVie Inc.